Abstract
Background All-cause mortality (ACM) scores are a useful tool for identifying individuals with decreased life expectancy. An interpretable score consisting of smartphone-obtainable variables could allow for long-term management of individual health and support the next generation of healthcare monitoring and preventative practices. The aim of this study was to develop a 10-year ACM risk score using the UK Biobank dataset, using only digitally-obtainable variables.
Methods The models were developed using the full UK Biobank cohort comprising nearly 500,000 individuals. We extracted 399 features from the dataset and, through a data-driven feature selection process with subsequent clinical review, identified 34 features for the final model. As part of the study, we compared two survival analysis approaches: Cox proportional hazards model and DeepSurv, a deep learning-based survival analysis algorithm.
Results Before feature selection, Cox performed similarly to DeepSurv, achieving a c-index of 0.771 (95% CI 0.770–0.772) and 0.774 (95% CI 0.772–0.775) on the test dataset, respectively. Using the selected 34 features, the c-index of Cox decreased slightly to 0.770 (95% CI 0.769–0.770) and DeepSurv to 0.758 (95% CI 0.755–0.762). The models show excellent calibration at 10 years.
Conclusions This study improves on a previous smartphone-compatible score, C-Score, by incorporating non-modifiable factors in addition to variables which can be actively modified to reduce risk. This score is comprehensive, easily interpretable and actionable, and as such, could provide a powerful tool for preventative healthcare.
Competing Interest Statement
MC, ND, AD, ABR, DM, MA, and DP are employees of Huma Therapeutics Ltd.
Funding Statement
This work was funded by Huma Therapeutics Ltd
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data comes from the UKB, approved under UKB application number 55668
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This research was funded by Huma Therapeutics Ltd.
Conflict of Interest: MC, ND, AD, ABR, DM, MA, and DP are employees of Huma Therapeutics Ltd.
Author Statement: All authors confirm they had access to the data and a role in writing the manuscript.
Data Availability
Data cannot be shared publicly owing to the violation of patient privacy and the absence of informed consent for data sharing.
